Argent BioPharma halves losses but faces funding ‘uncertainty’ by Adam Sheldon September 1, 2026September 3, 2026 Clinical biotech Argent BioPharma cut its annual loss by 57% to $7.7 million in FY26 as […]
Cann Group entering FY27 with ‘real momentum’, chairman says after year of financial juggling by Steve Jones August 31, 2026August 31, 2026
BLS triples profit, tips revenue to grow up to 55% in FY27 by Adam Sheldon August 31, 2026August 31, 2026
End in sight for Avecho as Phase III CBD trial moves into final stage by Adam Sheldon August 31, 2026August 31, 2026
Losses narrow for ECS Botanics as firm remains bullish despite market challenges by Steve Jones August 31, 2026August 31, 2026
‘Race to the bottom’ not for us, says Vitura as firm moves away from ‘cheap and cheerful’ market by Steve Jones August 28, 2026August 28, 2026
Neurotech shares jump 25% as chairman speaks of ‘considerable opportunity’ by Steve Jones August 27, 2026August 27, 2026
Prescriber college praises DVA cannabis guidance as ‘thoughtful and clinically useful’ by Steve Jones August 27, 2026August 27, 2026
Cannim saga takes new twist with firm set for sale to mystery UK buyer by Adam Sheldon August 26, 2026August 26, 2026
